Primate T-lymphotropic virus
Primate T-lymphotropic virus | |
---|---|
a micrograph showing both Human T-lymphotropic virus 1 and HIV | |
Scientific classification | |
(unranked): | Virus |
Realm: | Riboviria |
Kingdom: | Pararnavirae |
Phylum: | Artverviricota |
Class: | Revtraviricetes |
Order: | Ortervirales |
Family: | Retroviridae |
Subfamily: | Orthoretrovirinae |
Genus: | Deltaretrovirus |
Groups included | |
|
The primate T-lymphotropic viruses (PTLVs) are a group of
HTLVs have evolved from STLVs by
HTLVs belong to the genus Deltaretrovirus. The only other recognized species in the genus is Bovine leukemia virus, an economically-important cattle pathogen. As its name suggests, this virus causes leukemia in cows.[4]
General virology
This section is missing information about more on the fresh new genes, like Tax and Rex.(January 2023) |
HTLV-1 is the prototypical PTLV, from which comparisons are drawn for the newly-known types. A retrovirus, PTLV shares the common gag-pro-pol-env set of genes, yet shows great complexity in the unique 3' end. These new proteins provide a great source of new adaptive function:[5]
- Tax, the transactivator, is common to all Deltaretrovirus. In a HTLV-1 infection, it is the first protein to be expressed, and in turn is responsible for the expression of the provirus at the LTR during the early phase.[6]
- Rex is also common to all extant Deltaretrovirus. As it gets expressed, Rex binds mRNA to control the extent of splicing.[6]
- HBZ is the first novel protein, only common among PLTV. It encodes a basic leucine zipper, and is known to be enhance HLTV-1 replication and oncogenity. It is encoded in the opposite ("antisense") direction compared to all other ORFs.[6]
- p12, p8, p30, p13 are the newest class of proteins only found in HTLV-1.[7]
HTLV-1 has three tandem imperfect 21-base repeats as the long terminal repeat, but other PTLVs only have two.[1]
The lifecycle is common to retroviruses, starting at the
Nomenclatural clarification
The use of "HTLV-3" can cause some confusion, because the name HTLV-III was one of the names for
PTLV-1
PTLV-1 is the medically most important species in the class. Discovered by
HTLV-1 has seven reported subtypes (subtypes A through G).[17] The great majority of infections are caused by the cosmopolitan subtype A.[18] The HTLV-I/STLV-I history might suggest a simian migration from Asia to Africa not much earlier than 19,500–60,000 years ago.[19]
HTLV-2
Discovered in 1982,
HTLV-3
HTLV-3 was discovered in 2005 in rural Cameroon, and were, it is presumed, transmitted from monkeys to hunters of monkeys through bites and scratches.[25][26] Multiple strains have been identified.[27] A strain has been fully sequenced.[28][29]
PTLV-3 is about 40% different from PTLV-1 and -2. It occasionally cross-reacts with HTLV-2 tests. It is not yet known how much further transmission has occurred among humans, or whether the virus can cause disease.[1]
HTLV-4
HTLV-4 was discovered at the same site as HTLV-3 in 2005. Even less is known about this virus, as no simian counterpart has ever been found As of 2011[update]. ICTV does not recognize it as a species. The sequence is, however, available.[1]
STLV-5
STLV-5 is a name used for a highly divergent PTLV-1 strain isolated from
Transmission
HTLV-1 and HTLV-2 can be transmitted
Epidemiology
Two HTLVs are well established. HTLV-1 and HTLV-2 are both involved in actively spreading epidemics, affecting 15–20 million people worldwide.[35]
HTLV-1 is the more clinically significant of the two: at least 500,000 of the individuals infected with HTLV-1 eventually develop an often rapidly fatal leukemia, while others will develop a debilitative myelopathy, and yet others will experience uveitis, infectious dermatitis, or another inflammatory disorder. HTLV-2 is associated with milder neurologic disorders and chronic pulmonary infections. In the United States, HTLV-1/2 seroprevalence rates among volunteer blood donors average 0.016 percent.[citation needed]
No specific illnesses have yet been associated with HTLV-3 and HTLV-4.
Vaccination and treatments
While there is no present licensed vaccine, there are many factors which make a vaccine against HTLV-1 feasible. The virus displays relatively low antigenic variability, natural immunity does occur in humans, and experimental vaccination using envelope antigens has been shown to be successful in animal models. Plasmid DNA vaccines elicit potent and protective immune responses in numerous small-animal models of infectious diseases. However, their immunogenicity in primates appears less potent. In the past two decades a large initiative has been put forth to understand the biological and pathogenic properties of the human T-cell lymphotropic virus type 1 (HTLV-1); this has ultimately led to the development of various experimental vaccination and therapeutic strategies to combat HTLV-1 infection. These strategies include the development of envelope glycoprotein derived B-cell
Potential treatments include
References
- ^ PMID 21994771.
- from the original on 2017-08-29. Retrieved 2017-09-09.
- PMID 17376384.
- PMID 31775783.
- PMID 23966842.
- ^ PMID 22973269.
- PMID 23248621.
- PMID 21114861.
- ^ "Primate T-lymphotropic virus 1 ~ ViralZone". viralzone.expasy.org.
- PMID 30217825.
- ^ Human+T-Lymphotropic+Virus+Type+III at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- ^ Human+T+Lymphotropic+Virus+Type+IV at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- PMID 23173397.
- PMID 6261256.
- PMID 21212437.
- PMC 4042625.
- PMID 17376384.
- PMID 20610824.
- PMID 10723738.
- PMID 6981847.
- ^ "HTLV Type I and Type II". NORD (National Organization for Rare Disorders). Retrieved 2019-02-22.
- PMID 18755983.
- ^ "Human T-cell leukemia virus type 2". US Department of Health and Human Services | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program. Retrieved 2019-02-22. This article incorporates text from this source, which is in the public domain.
- PMID 20692726.
- PMID 18456423.
- (PDF) from the original on 2011-07-15. Retrieved 2010-12-10.
- (PDF) from the original on 2019-09-01. Retrieved 2019-09-01.
- PMID 16973592.
- PMID 18417569.
- from the original on 2012-10-06. Retrieved 2010-12-10.
- PMID 15809908.
- ^ "Die Vorteile eines GPS-Tracking-Halsbandes für Hunde - HTLV1 Hunde GPS Tracker Vergleich". Archived from the original on 2015-11-02. Retrieved 2015-11-04.
- ^ "Archived copy". Archived from the original on 2015-11-20. Retrieved 2015-11-04.
{{cite web}}
: CS1 maint: archived copy as title (link) - S2CID 6183061.
- PMID 8797723.
- (PDF) from the original on 2015-09-10. Retrieved 2014-03-05.
- ^ "Nervous System Disease: A New Outlet for an Old Drug?". Archived from the original on 2018-01-18. Retrieved 2018-03-09.
- PMID 22214262.
- PMID 22753721.
- PMID 21994743.
External links
- human T-cell lymphotrophic virus at eMedicine
- International Retrovirology Association
- Human+T-lymphotropic+virus+1 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- Human+T-lymphotropic+virus+2 at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- "Human T-lymphotropic virus 1". NCBI Taxonomy Browser. 11908.
- "Human T-lymphotropic virus 2". NCBI Taxonomy Browser. 11909.
- "Human T-lymphotropic virus 3". NCBI Taxonomy Browser. 28332.
- "Human T-lymphotropic virus 4". NCBI Taxonomy Browser. 318279.
- "Untyped Human T-lymphotropic virus". NCBI Taxonomy Browser. 318275.